Skip to main content
. 2019 Apr 9;321(14):1391–1399. doi: 10.1001/jama.2019.3241

Figure 4. Immunotherapy and Tumor Mutational Burden.

Figure 4.

Because both programmed death-ligand 1 (PD-L1) expression level and tumor mutational burden (TMB) are potentially predictive biomarkers of immunotherapy response, the relationship between the 2 was investigated. A, There was no difference in the median TMB between the PD-L1–negative and –positive tumors. The heavy horizontal line is the median, the extremes of the box correspond to the 25th and 75th percentiles of the data, and the error bar extends to 1.5 times the interquartile range (IQR) from the edge of the box. B, Among patients who received PD-1/PD-L1–targeting therapy, those with a TMB (in mutations/Mb) greater than 20 (n = 161) had a longer overall survival from start of therapy than those with a TMB less than 20 (n = 1116) (median observation time for TMB ≥ 20: 14.3 months [IQR, 7.8-28.5] and for TMB < 20: 17.0 months [IQR, 7.9-30.0]).